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Abstract Granulocyte colony-stimulating factor (G-CSF) has 
been recently shown to induce the high-affinity Fc receptor for 
IgG (FcTRI/CD64) in human polymorphonuclear neutrophils 
(PMN). To elucidate the molecular mechanisms whereby G-CSF 
exerts this effect, we examined whether the cytokine induces the 
binding of transcription factors to the IFNy response region 
(GRR), a well characterized regulatory element in the FcTRI 
promoter that is responsible for the transcriptional induction of 
this gene. Using electrophoretic mobility shift assays, we show 
that in human PMN, G-CSF activates a GRR-binding complex 
which contains members of the signal transducer and activator of 
transcription (STAT) family of proteins, namely STAT1 and 
STAT3. In keeping with this result, treatment of neutrophils with 
G-CSF led to tyrosine phosphorylation of STAT3, as determined 
by immunoprecipitation followed by immunoblotting with anti- 
phosphotyrosine antibodies. This is the first demonstration that 
in human neutrophils, the induction by G-CSF of FcTRI gene 
expression may be mediated by the binding of STAT1 and 
STAT3 to the GRR sequence. 
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1. Introduction 
In recent years, many studies have established that under 
appropriate stimulatory conditions, human polymorphonu- 
clear neutrophils (PMN) can synthesize cytokines, as well as 
several other proteins that are involved in their effector func- 
tions [1,2]. One such molecule is the high-affinity receptor for 
the Fc portion of IgG, FeyRI/CD64, which mediates phago- 
cytosis and antibody-dependent cellular cytotoxicity in acti- 
vated granulocytes [3,4]. Whereas this receptor is rarely de- 
tectable on mature PMN, its surface expression can be greatly 
upregulated by interferon-y (IFNy), both in vitro and in vivo 
[5-8]. This action of IFNy has been shown to involve the 
binding of the activated transcription factor, STAT1, to the 
IFNy response region (GRR) of the FcyRI gene promoter [9], 
resulting in an increased transcription of the FcTRI gene [8]. 
Although the transcriptional activation of the FcyRI/CD64 
gene has long been considered an IFNy-specific effect in mye- 
lomonocytic ells, it has been recently reported that granulo- 
cyte colony-stimulating factor (G-CSF) also has the ability to 
induce Fcq, RI mRNA accumulation and surface expression in 
mature neutrophils [10]. The present work was therefore un- 
dertaken to define which transcription factors are involved in 
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the G-CSF-mediated induction of FcTRI/CD64 gene expres- 
sion in human neutrophils. 
2. Materials and methods 
2.1. Cells and reagents 
Neutrophils were isolated from buffy coats of healthy donors under 
endotoxin-free conditions, as previously described [11]. Highly puri- 
fied PMN (>99.5% pure) were resuspended in RPMI 1640 medium 
containing 10% low-endotoxin fetal calf serum (FCS, Hyclone La- 
boratories Inc., Logan, UT, USA), and stimulated for the indicated 
times with 1000 U/ml recombinant human G-CSF (Granulokine, 
Hoffman-La Roche, Basel, Switzerland), or with 100 U/ml recombi- 
nant human IFNy (kindly provided by Dr. G. Garotta, Hoffman-La 
Roche, Basel, Switzerland). An anti-STAT1 rabbit polyclonal IgG 
(raised against amino acids 688 710), and two anti-STAT3 rabbit 
polyclonal IgG (C-20 and K-15, raised against amino acids 750-769 
and 626-640, respectively) were purchased from Santa Cruz Biotech- 
nology Inc. (Santa Cruz, CA, USA). 
2.2. Northern blot analyses 
Northern blots were performed as described [11]; FcTRI, gp91-phox 
(the heavy chain subunit of the cytochrome b component of the 
NADPH oxidase) and actin mRNAs were detected by sequential hy- 
bridizations of the nylon filters with purified, denatured, and 
[32P]dCTP-labeled cDNA fragments. 
2.3. CeH fractionation and electrophoretic mobility shift assays 
(EMSA) 
After stimulation with 1000 U/ml G-CSF or its diluent (20 min, 
37°C), neutrophils (10S/condition) were diluted in ice-cold phosphate- 
buffered saline (PBS) and centrifuged (500xg, 10 min, 4°C). Cells 
were resuspended in 1.3 ml of relaxation buffer [12] supplemented 
with an antiprotease and antiphosphatase cocktail (3 mM diisopro- 
pyl-fluorophosphate (DFP), 10 ~tg/ml leupeptin, 10 I.tg/ml pepstatin A, 
0.25 mM phenyl-methyl-sulfonyl-ftuoride (PMSF), 33 ~tg/ml aproti- 
nin, 1 mM Na3VO4 and 50 mM NaF), and disrupted in a nitrogen 
bomb (Parr Instruments, Mobile, IL, USA) as described [12]. The 
cavitates were centrifuged (12000 × g, 30 min, 4°C) to pellet unbroken 
cells, nuclei, and granules. The resulting supernatants (referred to as 
cytoplasmic preparations) were either processed for immunoprecipita- 
tion, or (when used in EMSA experiments) further concentrated using 
Microcon 10 columns (Amicon, Beverly, MA, USA). EMSAs were 
performed as described previously [13], using either the 39-bp GRR 
element of the FcyRI/CD64 gene promoter [14], or the high-affinity c- 
sis-inducible lement (hSIE), m67 [15], as oligonucleotide probes. The 
murine leukemia virus upstream conserved region (UCR) [16] was 
used as a non-specific ompetitor. 
2.4. Immunoprecipitations and immunoblots 
Cytoplasmic preparations (2 mg/condition) were incubated with 20 
~tl of a 50% slurry of protein A agarose (Boehringer, Mannheim, 
Germany) in the presence of a 1:300 dilution of anti-STAT3 antibody 
(C-20), for 4 h at 4°C on a rotating wheel. Immunoprecipitates were 
washed six times with 1 ml of washing buffer (150 mM KCI, 10 mM 
Tris pH 7.4, 10% glycerol, 0.05% Triton X-100, 0.1% BSA, 1 mM 
Na3VO4 and 50 mM NaF) prior to electrophoretic separation on 
7.5% SDS-PAGE and subsequent transfer to nitrocellulose by electro- 
blotting. Nitrocellulose membranes were blocked in 5% BSA, 20 mM 
Tris pH 7.6, 137 mM NaC1, 0.05% Tween-20 for 4 h at room tem- 
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perature and further incubated (overnight at 4°C) with a 1:1000 dilu- 
tion of anti-phosphotyrosine a tibody 4G10 (Upstate Biotechnology 
Inc., Lake Placid, NY, USA), or with a 1:2000 dilution of anti- 
STAT3 antibody (K-15). Antibody binding was visualized by perox- 
idase-conjugated anti-mouse or anti-rabbit IgG (1:15000) and re- 
vealed using the enhanced chemiluminescence system (Amersham, 
Little Chalfont, UK) according to the manufacturer's in tructions. 
3. Results 
Fig. 1 shows a representative Northern blot performed on 
total RNA purified from human neutrophils cultured for up 
to 18 h in the presence or absence of G-CSF, or (for compar- 
ison) with IFN 7. In agreement with a recent report [10], G- 
CSF induced the selective accumulation of FcyRI mRNA in 
human PMN. This effect of the cytokine was already detect- 
able after 1 h, and increased thereafter, peaking at about 5 h. 
In contrast, G-CSF failed to influence the steady-state l vels 
of mRNA encoding the NADPH oxidase component, gp91- 
phox. By comparison, IFN 7 induced the accumulation of 
mRNA transcripts encoding both FcyRI and gp91-phox, as 
previously described [8,11]. 
To elucidate the molecular mechanisms whereby G-CSF 
induces FcTRI/CD64 mRNA in PMN, we examined whether 
the cytokine could induce the binding of protein complexes to 
the GRR. This regulatory element, located within the promo- 
ter of the FcRI gene, contains a typical 9-bp IFNT-activated 
sequence (GAS) consensus core, and is necessary and suffi- 
cient for IFNy-induced activation of FcTRI/CD64 [14,17-20]. 
Cytoplasmic preparations from untreated and G-CSF-treated 
neutrophils were therefore incubated with a 32P-labeled GRR 
probe and analyzed in EMSA. As shown in Fig. 2 (left panel), 
a GRR-binding complex was induced in G-CSF-treated cells, 
compared to untreated cells. This DNA-binding complex was 
specific, since it was competed by an excess of unlabeled 
GRR, but not by an excess of unrelated oligonucleotide 
(UCR) [16]. 
Recent studies have shown that stimulation of monocytes 
with IL-10 results in FcTRI induction [21], as well as in the 
binding to the GRR element of protein complexes containing 
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Fig. 1. Effect of G-CSF on the steady-state levels of FcyRI/CD64 
mRNA in human PMN. Neutrophils (106 cells/300 pl) were cultured 
with 1000 U/ml G-CSF, 100 U/ml IFNy, or their diluent (RPMI 
1640), for the indicated times. Total RNA was isolated and ana- 
lyzed by Northern blot, using FcTRI/CD64, gp91-phox and actin 
cDNA probes. The experiment depicted in this figure is representa- 
tive of two. 
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Fig. 2. Characterization f DNA-binding protein complexes induced 
by G-CSF in human PMN. Neutrophils were incubated for 20 min 
at 37°C in the presence or absence (C) of 1000 U/ml G-CSF, prior 
to disruption by nitrogen cavitation. The resulting cytoplasmic prep- 
arations were incubated with z2P-labeled oligonucleotides (using 60 
/.tg/lane for GRR probe and 40 Bg/lane for hSIE/m67 probe), and 
analyzed in EMSA. For competition and supershifting studies, cyto- 
plasmic preparations were first incubated (30 min, 4°C) with unla- 
beled competitor (at a 100-fold molar excess), or with anti-STAT1, 
anti-STAT3, or normal rabbit serum (NRS), prior to incubation 
with the labeled GRR or hSIE/m67 probes. The experiment de- 
picted in this figure is representative of three. 
STAT1 and STAT3 [20,22,23]. We therefore investigated 
whether the same proteins can bind the GRR sequence fol- 
lowing G-CSF treatment of human PMN. To this end, anti- 
bodies to STAT1 and STAT3 were added to PMN cytoplas- 
mic preparations prior to incubation with the 32p-labeled 
GRR probe and subsequent EMSA analysis. As shown in 
Fig. 2 (left panel), anti-STAT1 antibodies eliminated the lower 
part of the specific GRR-binding complex, whereas the upper 
part could be supershifted by anti-STAT3 antibodies. More- 
over, when both antibodies were used in combination, the 
whole GRR-binding complex was efficiently supershifted. By 
comparison, pretreatment of the same cytoplasmic prepara- 
tions with normal rabbit serum had no detectable effect. These 
results clearly show that G-CSF treatment of PMN results in 
the binding of STAT1 and STAT3 to the GRR. This conclu- 
sion was further supported by EMSA experiments in which 
m67, a synthetic derivative of the hSIE, was used as a probe. 
This element is known to bind with particularly high affinity 
the STAT proteins activated by a variety of cytokines [15], 
and has been previously utilized to study G-CSF-induced 
STAT protein activation in the human myeloid leukemia 
cell line, AML-193 [24], and more recently, in human neutro- 
phils [25]. Fig. 2 (right panel) shows that cytoplasmic prepara- 
tions from G-CSF-treated PMN interacted with the hSIE/m67 
probe to form a DNA-binding complex identical in composi- 
tion to that observed using the GRR probe. Indeed, supershift 
experiments identified both STAT1 and STAT3 as constitu- 
ents of this complex. Noteworthy is that an excess of unla- 
beled GRR oligonucleotide probe did not completely compete 
out the m67-binding complex, confirming that hSIE/m67 has 
a higher affinity than GRR for STAT proteins (Fig. 2, right 
panel). 
Since the binding of STAT3 to GAS elements i known to 
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Fig 3 Effect of G-CSF on the tyrosine phogphorylation f STAT3 
in human PMN. Neutrophils were incubated in the presence or ab- 
sence of G-CSF and disrupted as described in the legend to Fig. 2. 
The resulting cytoplasmic preparations were immunoprecipitated 
with an anti-STAT3 antibody and processed for immunoblot using 
anti-phosphotyrosine antibodies. The nitrocellulose membrane was 
then stripped and reprobed using an anti-STAT3 antibody. 
depend upon its phosphorylation tyrosine residues [24,26], 
we examined whether G-CSF treatment of PMN might induce 
the tyrosine phosphorylation of STAT3. For this purpose, 
cytoplasmic preparations from PMN treated for 20 min 
with G-CSF (or its diluent) were immunoprecipitated with 
anti-STAT3 antibodies, and processed for immunoblot using 
an anti-phosphotyrosine a tibody (Fig. 3). To ascertain that 
equal amounts of immunoprecipitated proteins were loaded 
on the gels, the blots were stripped and reprobed with anti- 
STAT3 antibodies. The results of these experiments make it 
clear that in human PMN, STAT3 becomes tyrosine phos- 
phorylated in response to G-CSF. 
4. Discussion 
In the present study, we show that in G-CSF-treated human 
PMN, the inducible accumulation FcyRI/CD64 mRNA is pre- 
ceded by the binding of STAT1 and STAT3 to the GRR, a 
GAS-related enhancer sequence located in the FcyRI gene 
promoter. These findings, in conjunction with a recent study 
[10], strongly suggest hat the binding of STAT1 and STAT3 
to the GRR plays a major role in the induction by G-CSF of 
FcyRI/CD64 gene expression in human PMN. That both IL- 
l0 and IFNy induce FcyRI/CD64 gene expression in mono- 
cytes, presumably through the binding of DNA-binding com- 
plexes containing STAT1 and STAT3 to the GRR [20-23], 
further supports this conclusion. 
In addition to showing that human PMN express ubstan- 
tial amounts of STAT3 protein, our immunoprecipitation 
studies revealed that STAT3 becomes tyrosine phosphorylated 
following G-CSF treatment, in agreement with observations 
made in other cell types [24,27]. Although the G-CSF receptor 
lacks intrinsic tyrosine kinase activity, G-CSF has been shown 
to promote the activation of JAK2 in the AML-193 human 
myeloid leukemia cell line [24], in the immature hematopoietic 
cell line BAF/BO3 [27], and more importantly, in human neu- 
trophils [28]. In view of the ability of JAK2 to phosphorylate 
STAT proteins on tyrosine residues [9], these observations 
raise the possibility that in neutrophils timulated by G- 
CSF, there might be a direct link between the onset of 
JAK2 kinase activity and the activation of DNA-binding 
complexes containing STAT1 and STAT3. 
While this article was in preparation, Tweardy and collea- 
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gues [25] reported that G-CSF treatment of human neutro- 
phils induces a DNA-binding activity that interacts with a 
hSIE/m67 oligonucleotide probe. Because this hSIE/m67-spe- 
cific DNA-binding activity was recognized neither by an anti- 
STAT3 antibody (the same that was used in this study), nor 
by antibodies directed against other members of the STAT 
family, the authors concluded that the hSIE/m67-binding 
complex contains a novel STAT-like protein present in mature 
neutrophils [25]. While the results of the above study contrast 
with those reported herein in many respects, these apparent 
discrepancies are likely to reflect fundamental differences in 
the respective procedures used to disrupt neutrophils. In this 
regard, it is noteworthy that our preliminary studies, in which 
whole-cell neutrophil extracts were prepared by freeze-and- 
thaw cycles, which results in the partial solubilization of the 
granules and concomitant release of proteolytic enzymes, 
yielded identical results to those reported by Tweardy et al. 
[25]. However, by preparing neutrophil lysates by nitrogen 
cavitation, which preserves neutrophil granule integrity [12], 
we were able to detect STAT3 in supershift and immunoblot 
experiments, as demonstrated herein. Thus, we propose that 
in neutrophils disrupted by freeze-and-thaw cycles or deter- 
gent lysis, STAT3 is subjected to proteolytic leavage and thus 
becomes not recognizable by anti-STAT3 antibodies. 
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